此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

ETEC Logistics Trial (TREK) (Trek)

2012年3月13日 更新者:Intercell USA, Inc.

A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting

This is a multicenter, double-blind, randomized, placebo-controlled field trial to evaluate the epidemiology of natural infection with ETEC occurring after transcutaneous immunization in a field setting.

研究概览

详细说明

The primary objectives of the study are to evaluate the incidence of ETEC illness in a field setting and to compare the safety of LT delivered by TCI with placebo. The secondary objectives include, but are not limited to:

evaluate the stool frequency per episode of ETEC illness in placebo recipients, to evaluate the immunogenicity of LT delivered by TCI, to evaluate the incidence of IBS following travel to areas of ETEC endemnicity, and to evaluate the incidence of VPO in placebo and LT patch recipients.

研究类型

介入性

注册 (实际的)

201

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Antigua Guatemala、危地马拉、03001
        • Private Clinic Antigua
    • Guanajuata
      • San Miguel de Allende、Guanajuata、墨西哥、37700
        • Private Clinic San Miguel
    • Jalisco
      • Guadalajara、Jalisco、墨西哥、44690
        • Private Clinic Guadalajara
    • Marina Vallarta
      • Puerto Vallarta、Marina Vallarta、墨西哥、48334
        • AmeriMed Hospital
    • Morelos
      • Cuernavaca、Morelos、墨西哥、62250
        • Private Clinic Cuernavaca
    • Quintana Roo
      • Cancun、Quintana Roo、墨西哥、77500
        • Hospital Americano
    • California
      • Long Beach、California、美国、90806
        • West Coast Clinical Trials
    • Illinois
      • Chicago、Illinois、美国、60610
        • Radiant Research
    • Maryland
      • Baltimore、Maryland、美国、21205
        • Johns Hopkins University, Bloomberg School of Public Health
    • Minnesota
      • Minneapolis、Minnesota、美国、55430
        • Twin Cities Clinical Research
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • Advanced Biomedical Research
    • New York
      • Ithica、New York、美国、14850
        • Asthma Allergy & Associates
    • Ohio
      • Columbus、Ohio、美国、43212
        • Radiant Research
    • Texas
      • Dallas、Texas、美国、75235
        • Radiant Research
      • Houston、Texas、美国、77024
        • Breco Research
      • Houston、Texas、美国、77030
        • Center for Infectious Diseases, The University of Texas Health Science Center at Houston
      • San Antonio、Texas、美国、78229
        • Radiant Research
    • Utah
      • Salt Lake City、Utah、美国、84124
        • Jean Brown Research
    • Washington
      • Tacoma、Washington、美国、98418
        • Northwest Kinetics

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 64年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy adult men and women 18-64 years of age inclusive at screening
  • Signed Informed Consent form
  • Planned travel to an area within 2 ½ hours traveling distance of Cuernavaca or Guadalajara, Mexico or Antigua, Guatemala (minimum stay of 7 days)
  • If female who is not post-menopausal or surgically sterile, negative pregnancy test (within 24 hours prior to vaccination) and agreement to employ an effective form of birth control or practice abstinence through the end of the study.

Exclusion Criteria:

  • Clinically significant abnormalities as determined by the Investigator/clinician during physical inspection
  • Received investigational product from 30 days before date of first vaccination or during the entire study period
  • Ever received LT, ETEC, or cholera vaccine
  • History of traveler's diarrhea within the previous year
  • Travel to a developing country within the last year
  • Women who are pregnant or breastfeeding
  • History of achlorhydria
  • Evidence of immunosuppression, including concomitant immunosuppressive therapy; fever > 99.5°F (37.5°C) on day of vaccination
  • Current problems with alcohol or substance abuse
  • An employee of the study clinic
  • Sensitivity or allergy to any of the vaccine components
  • History of significant blood loss, blood product donation, or blood product recipient in the previous 60 days
  • Planned use of Imodium or antibiotics for self treatment of diarrhea during the study period
  • Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent appropriate dermatologic monitoring of the vaccination sites; and
  • Medical history of acute or chronic GI illness or major GI surgery.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 分配:随机化
  • 介入模型:阶乘赋值
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Group 1
Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
安慰剂比较:Group 2
Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Incidence of Enterotoxigenic Escherichia coli (ETEC) illness defined as a diarrheal episode associated with an LT, LT/ST, or ST-positive ETEC strain isolated from a sample of a stool
大体时间:during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode.
during the diarrheal episode or within 48 hours after the last stool in the diarrheal episode.
Safety of heat-labile enterotoxin of Escherichia coli (LT) delivered by transcutaneous immunization (TCI) vs placebo
大体时间:From vaccination 1 to completion of Day 180 follow-up, about a seven month time period
From vaccination 1 to completion of Day 180 follow-up, about a seven month time period

次要结果测量

结果测量
大体时间
Stool frequency per episode of ETEC illness in placebo recipients
大体时间:Duration of stay in Mexico or Guatemala assessed up to four weeks
Duration of stay in Mexico or Guatemala assessed up to four weeks
Immunogenicity of LT delivered by TCI
大体时间:at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival
at least three weeks prior to arrival in country, arrival in Mexico or Guatemala, and 5 to 18 days after arrival
Incidence of irritable bowel syndrome following travel to areas of ETEC endemnicity.
大体时间:Baseline through six months post return from Latin America. A period of about six months.
Baseline through six months post return from Latin America. A period of about six months.
Incidence of vaccine preventable outcome in placebo and LT patch recipients.
大体时间:Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days.
Duration of each individual participant stay in Mexico or Guatemala ranging from 7 to 28 Days.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Herbert L. DuPont, MD、Center for Infectious Diseases, The University of Texas Health Science Center at Houston
  • 首席研究员:Robin McKenzie, MD、Johns Hopkins University, Bloomberg School of Public Health
  • 首席研究员:Rama Yerramsetti、Breco Research, Houston, TX
  • 首席研究员:William P Jennings、Radiant Research, San Antonio, TX
  • 首席研究员:Yu-Luen Hsu、West Coast Clinical Trials, Long Beach, CA
  • 首席研究员:Christopher A Smith、Asthma & Allergy Associates, Ithaca, NY
  • 首席研究员:Benno G Roesch、Advanced Biomedical Research, Hackensack, NJ
  • 首席研究员:Jeffrey G Geohas、Radiant Research, Chicago, IL
  • 首席研究员:Gilbert Podolsky、Jean Brown Research, Salt Lake City, UT
  • 首席研究员:Thomas Lagen、Northwest Kinetics, Tacoma, WA
  • 首席研究员:Roy M Fleischmann、Radiant Research, Dallas, TX
  • 首席研究员:Douglas R Schumacher、Radiant Research, Columbus, OH
  • 首席研究员:Norman M Lunde、Twin Cities Clinical Research, Minneapolis, MN
  • 首席研究员:Francisco G Sandoval、Universidad Autonoma De Guadalajara, Mexico
  • 首席研究员:Juan Hector M Romero、Universidad Autonoma Guadalajara, Mexico
  • 首席研究员:Jaime B Gerson、University of Texas, Cuernavaca, Mexico
  • 首席研究员:Edwin Asturias、Universidad del Valle de Guatemala (Antigua)
  • 首席研究员:Roberto Garcia、AmeriMed Puerto Vallarta, Mexico
  • 首席研究员:Martha V Serrato、Hospital Americano, Cancun, Mexico
  • 首席研究员:Robert Maxwell、Private Clinic, San Miguel de Allende, Mexico

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2006年5月1日

初级完成 (实际的)

2007年1月1日

研究完成 (实际的)

2007年12月1日

研究注册日期

首次提交

2007年8月13日

首先提交符合 QC 标准的

2007年8月14日

首次发布 (估计)

2007年8月15日

研究记录更新

最后更新发布 (估计)

2012年3月14日

上次提交的符合 QC 标准的更新

2012年3月13日

最后验证

2012年3月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅